Paper Details

  1. Home
  2. Paper Details

Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.

Author: AhreA, BjöremanM, BjörkholmM, BrenningG, GahrtonG, GyllenhammarH, JohanssonB, JuliussonG, JärnmarkM, OsterborgA

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 86 patients with multiple myeloma stage III comparing combination chemotherapy with intermittent oral melphalan and prednisone found no significant difference in response rates, duration of response, or survival times. However, survival was significantly shorter for patients over 65 years old who received combination therapy.
Paper Details　
Original Abstract of the Article :
86 previously untreated patients with multiple myeloma stage III entered a randomized trial comparing combination chemotherapy (VMCP/VBAP) (n = 42) with intermittent oral melphalan and prednisone (MP) treatment (n = 44). The treatment gropus were well comparable with regard to major prognostic facto...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1600-0609.1989.tb01252.x

データ提供：米国国立医学図書館（NLM）

Multiple Myeloma: Comparing Treatment Regimens

Multiple myeloma is a complex and challenging cancer to treat. This study compared the effectiveness of two different chemotherapy regimens, alternating combination chemotherapy (VMCP/VBAP) and melphalan/prednisone (MP), in patients with stage III multiple myeloma. The study found no statistically significant difference in response rates, response duration, or overall survival between the two treatment groups. However, the study did observe a shorter survival time in the VMCP/VBAP group for patients older than 65 years, suggesting that this regimen might be less effective in this specific age group.

Optimizing Treatment for Multiple Myeloma

This study adds to the growing body of evidence supporting the use of MP therapy as a primary standard treatment for patients with multiple myeloma. The findings highlight the need for personalized treatment approaches, considering factors such as age and other prognostic indicators to optimize treatment outcomes.

Navigating the Desert of Cancer Treatment

The desert of cancer treatment is full of complexities and uncertainties. This study provides valuable insights into the efficacy of different treatment regimens and the importance of tailoring treatments to individual patients. Remember, consulting with a qualified oncologist and seeking personalized guidance is crucial in navigating this challenging terrain.

Dr.Camel's Conclusion

This randomized trial sheds light on the effectiveness of different chemotherapy regimens for multiple myeloma. While the findings suggest that MP therapy might be a better choice for certain patient populations, more research is needed to further refine treatment strategies. Navigating the desert of cancer treatment requires a multi-faceted approach, combining the latest research, personalized care, and a resilient spirit.

Date :
  1. Date Completed 1989-09-28
  2. Date Revised 2019-09-08
Further Info :

Pubmed ID

2670605

DOI: Digital Object Identifier

10.1111/j.1600-0609.1989.tb01252.x

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.